FeesSafety
Pluang+

Actinium advances ATNM-400 HER3-targeted radiotherapy with promising early prostate cancer data and expands pan-tumor study.

Market News
17 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
Actinium advances ATNM-400 HER3-targeted radiotherapy with promising early prostate cancer data and expands pan-tumor study.

Actinium Pharmaceuticals announced progress with ATNM-400, a HER3-targeted alpha radiotherapy for metastatic castration-resistant prostate cancer (mCRPC), showing encouraging initial clinical data with no dose-limiting toxicities and tumor uptake retention. They initiated the RADIANZ imaging study to explore ATNM-400's potential across multiple solid tumors beyond prostate cancer. The company also strengthened its scientific advisory board and leadership team to support pipeline development and expects key clinical milestones in 2027. Upcoming presentations will share further data on ATNM-400 and other pipeline programs, positioning Actinium for growth in targeted cancer therapies.

Actinium Pharmaceuticals' corporate update on ATNM-400 provides context for readers following health sector developments. For readers following health stocks, here is Pluang's market snapshot as of Nov 17, 2026 18:51 WIB: out of 150 priced health-sector US stocks, 51 rose and 91 fell today. Guardant Health Inc. (GH) rose 2.05% to USD 146.98 with a typical hold time of 10 days, contrasting with Medline Inc. (MDLN) and Elevance Health Inc. (ELV), which fell 1.86% to USD 38.44 and 1.85% to USD 438.01 respectively, with typical hold times of 7 and 13 days.

More News

Microsoft expands use of Haivision tech for live production of 600+ global events annually

Microsoft expands use of Haivision tech for live production of 600+ global events annually

Microsoft has expanded its partnership with Haivision by adopting the Makito ONE video transport platform, Makito X4 video encoders and decoders, Haivision Pro mobile transmitters, and Haivision Hub 360 for live production of over 600 global events e...

Market News
Bullish
1 hour ago
Piper Sandler upgrades Medtronic on growth from acquisitions and new treatments.

Piper Sandler upgrades Medtronic on growth from acquisitions and new treatments.

Piper Sandler upgraded Medtronic to Overweight with a $120 price target, citing strategic growth through acquisitions and product launches in vascular, heart rhythm, and robotic surgery. Medtronic's recent acquisition of Contego Medical expands its c...

Analyst Insights
Bullish
2 hours ago
NVIDIA forms new committee to oversee national security and export control compliance.

NVIDIA forms new committee to oversee national security and export control compliance.

NVIDIA's Board of Directors has established the National Security and Export Control Oversight Committee to manage the company's national security policies and export control compliance. Chaired by Suzanne Nora Johnson, the committee will oversee NVI...

Market News
Neutral
2 hours ago
Malaysia's e-commerce market to nearly double to $25.65B by 2032, driven by mobile shopping and digital payments.

Malaysia's e-commerce market to nearly double to $25.65B by 2032, driven by mobile shopping and digital payments.

Malaysia's e-commerce market is projected to grow from $13.85 billion in 2027 to $25.65 billion by 2032, with a CAGR of 13.12%. Growth is fueled by increased smartphone use, digital wallet adoption, expanding logistics, and social commerce. B2C remai...

Market News
Bullish
2 hours ago
Burning Rock schedules 2026 AGM on Dec 22 to approve auditor and re-elect directors

Burning Rock schedules 2026 AGM on Dec 22 to approve auditor and re-elect directors

Burning Rock Biotech Limited announced its 2026 Annual General Meeting will be held on December 22, 2026, at its Shanghai office. The meeting will cover ratifying Ernst & Young Hua Ming LLP as auditor for 2026, re-electing directors Zhihong Zhang and...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App